Chemical formula: C₂₄H₂₈N₂O₅ Molecular mass: 424.49 g/mol PubChem compound: 5362124
Benazepril is a prodrug which, after hydrolysis to the active substance benazeprilat, inhibits the angiotensin-converting enzyme (ACE) and so blocks the conversion of angiotensin I to angiotensin II. This reduces all the effects mediated by angiotensin II – i.e. vasoconstriction and production of aldosterone, which promotes the reabsorption of sodium and water in the renal tubules – and elevates cardiac output.
This medicinal substance has been classified in the anatomical therapeutic chemical (ATC) classification according to its main therapeutic use as follows:
| ATC code | Group title | Classification |
|---|---|---|
| C09AA07 | Benazepril | C Cardiovascular system → C09 Agents acting on the renin-angiotensin system → C09A ACE inhibitors, plain → C09AA ACE inhibitors, plain |
Competent medicine agencies globally have authorized commercialization of this active ingredient according to these medication package inserts (MPIs):
| Title | Information Source | Document Type | |
|---|---|---|---|
| LOTENSIN Tablet | FDA, National Drug Code (US) | MPI, US: SPL/PLR |
Benazepril is an active ingredient of these brands:
United States (US)
Brazil (BR)
Germany (DE)
Italy (IT)Japan (JP)
Netherlands (NL)
Poland (PL)
South Africa (ZA)Spain (ES)
Note the following: The list of brand names is continuously updated, and thus does not include the total of products circulating worldwide. |
© All content on this website, including data entry, data processing, decision support tools, "RxReasoner" logo and graphics, is the intellectual property of RxReasoner and is protected by copyright laws. Unauthorized reproduction or distribution of any part of this content without explicit written permission from RxReasoner is strictly prohibited. Any third-party content used on this site is acknowledged and utilized under fair use principles.
